Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded to “Buy” at StockNews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Other equities research analysts have also issued reports about the stock. Piper Sandler lifted their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a report on Tuesday. Truist Financial restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $188.62.

Jazz Pharmaceuticals Trading Down 1.5 %

Shares of Jazz Pharmaceuticals stock opened at $103.53 on Friday. Jazz Pharmaceuticals has a 1 year low of $102.86 and a 1 year high of $146.70. The firm has a market cap of $6.53 billion, a PE ratio of 21.35, a PEG ratio of 1.61 and a beta of 0.58. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The company has a 50 day simple moving average of $108.62 and a two-hundred day simple moving average of $116.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Analysts expect that Jazz Pharmaceuticals will post 15.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in Jazz Pharmaceuticals by 0.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 99 shares during the period. Waterfront Wealth Inc. grew its position in shares of Jazz Pharmaceuticals by 1.2% in the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after buying an additional 103 shares during the period. ProShare Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 1.4% in the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after buying an additional 105 shares during the period. Prime Capital Investment Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 4.3% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock worth $325,000 after buying an additional 108 shares during the period. Finally, Ontario Teachers Pension Plan Board grew its position in shares of Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after buying an additional 108 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.